DRUG-SHORTAGE CRISIS

APP Pharmaceuticals releasing more preservative-free methotrexate

Continuing to work with FDA to ease the ongoing shortage of injectable methotrexate, APP Pharmaceuticals this week released another 10,000 vials of preservative-free methotrexate (Methotrexate Injection), a drug used in the treatment of pediatric oncology and hematology. » More

CONTINUING EDUCATION

The latest FDA drug approvals: What you need to know

Of the 35 new molecular entities approved by FDA in 2011, 17 are considered groundbreaking because of their potential to make a real difference in the lives of patients.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

CLINICAL NEWS

Study: Adding prednisone to treatment improves rheumatoid arthritis symptoms

Patients’ rheumatoid arthritis symptoms improved after adding prednisone at the start of a methotrexate-based treatment strategy, according to research published in the March 6 issue of the Annals of Internal Medicine. » More

Aspirin may reduce incidence of strokes in postmenopausal women with high trans-fat intake

Postmenopausal women with a higher intake of trans fat have a higher incidence of ischemic stroke, but aspirin may reduce the adverse effects of trans fat, according to a new study. » More

FDA NEWS

FDA releases draft guidance on drug-safety issues

The FDA’s Center for Drug Evaluation and Research released a new draft guidance on how it develops and classifies drug-safety issues. » More

FDA approves first cell-based product to treat oral mucogingival conditions

FDA approved the first cell-based product made from allogeneic human cells and bovine collagen (Gintuit, Organogenesis) for the treatment of oral mucogingival conditions in adults, the agency announced last week. » More

FDA approves first generic Lexapro to treat depression, anxiety disorder

Teva/IVAX Pharmaceuticals gained FDA approval for the first generic version of Lexapro (Forest) to treat both depression and generalized anxiety disorder in adults. The company will have 180 days to exclusively sell the product. » More

MEETINGS

FIP planning centennial celebration in Amsterdam

The International Pharmaceutical Federation will celebrate its 100th anniversary at the Centennial Congress of Pharmacy and Pharmaceutical Sciences, scheduled October 3 through 8 in Amsterdam, The Netherlands. » More

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Voices

•	Anticoagulation Update
•	JP at Large
•	View from the Zoo
•	Viewpoints
•	Regulatory & Legal

Meetings & Events

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.